. 2018 Dec 18;69(8):1345–1352. doi: 10.1093/cid/ciy1066

Table 1.

Background and Clinical Characteristics

Variable	503	1018	3017	340		3025		3026			Escape (Median)^a	Suppressed (Median, Interquartile Range)
Gender	Female	Male	Male	Male		Male		Male			…	…
Race	Black or African American	Black or African American	Black or African American	American Indian/Alaska Native		White		White			…	…
				T1	T2	T1	T2	T1	T2	T3	…	…
Age (years)	52	53	48	48	48	39	39	42	42	47	48	50 (42–56)
CSF VL (copies/mL)	117	89	47	209	54	1295	<40	265	356	<40	117	<40^b
Plasma VL (copies/mL)	<40	<40	<40	62	<40	<40	<40	<40	<40	<40	<40	<40^b
CD4 (cells/mm³)	430	567	325	327		210	261	200	309	503	326	539 (389–693)^b
Nadir CD4 (cells/mm³)	298	296	150	103		12		10			127	133 (34–253)^c
CSF white blood cell count (cells/mm³)	3	134	1	1		87	4	2	1	2	2	1 (1–3)^b
Months on ART	12	13	32	83	85	19	28	23	31	83	23	62 (19–123)^d
ART regimen	EFV, FTC, TDF	EFV, FTC, TDF	EFV, FTC, TDF	DRV/r, TDF, FTC	DRV/r, TDF, FTC	DRV/r, TDF, FTC	DRV/r, TDF, FTC	DRV/r, TDF, FTC	DRV/r, TDF, FTC	BIC, FTC, TAF	…	…
ART regimen resistance mutations	N/A	N/A	N/A	N/A	N/A	None	N/A	M184V	M184V	N/A	…	…

Abbreviations: ART, antiretroviral therapy; BIC, bictegravir; CSF, cerebrospinal fluid; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; FTC, emtricitabine; N/A, not measured; T1, time point 1; T2, time point 2; T3, time point 3; TDF, tenofovir disoproxil fumarate; VL, viral load.

^aFor participants with multiple escape time points, an average value was generated and used to calculate the median.

^bA total of 95 participants.

^cA total of 94 participants.

^dA total of 92 participants.